PAVmed (NASDAQ:PAVM) versus Carmell (NASDAQ:CTCX) Critical Contrast

Carmell (NASDAQ:CTCX) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Valuation and Earnings

This table compares Carmell and PAVmed”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carmell	N/A	N/A	-$15.44 million	N/A	N/A
PAVmed	$3.83 million	4.24	-$64.18 million	($9.10)	-0.19

Carmell has higher earnings, but lower revenue than PAVmed.

Analyst Recommendations

This is a summary of current recommendations for Carmell and PAVmed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carmell	0	0	0	0	N/A
PAVmed	0	0	1	1	3.50

PAVmed has a consensus price target of $21.00, suggesting a potential upside of 1,121.43%. Given PAVmed’s higher possible upside, analysts clearly believe PAVmed is more favorable than Carmell.

Volatility and Risk

Carmell has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Profitability

This table compares Carmell and PAVmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carmell	N/A	-148.47%	-40.47%
PAVmed	-1,508.12%	N/A	-102.44%

Insider & Institutional Ownership

24.2% of Carmell shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 29.0% of Carmell shares are owned by insiders. Comparatively, 12.6% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

PAVmed beats Carmell on 6 of the 11 factors compared between the two stocks.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.